Novavax, Inc. announced that its partners secured regulatory clearance for the XFG-adapted Nuvaxovid vaccine in the United States, European Union and Japan. Shares dipped 0.6% to $9.00 as of 11:58 a.m. EDT.
Regulatory clearance is complete; royalties now depend on partner-led demand.
| Revenue channel | Economics | What changed |
|---|---|---|
| Sanofi royalties | High teens–low 20s % of global net sales | U.S. and EU seasonal approvals enable sales |
| Takeda | Royalties plus annual approval milestones | Japan approval supports 2026–2027 season |
| Sanofi supply | Recorded as product sales | Commercial supply planned this season |
| Technology transfer | $75M potential milestone | Expected mid-2027 |
Excludes Sanofi supply sales, royalties and milestones.
Versus $751M at Dec. 31, 2025
| Q2 2026 | Value | Year-over-year |
|---|---|---|
| Total revenue | $57M | −76% |
| Product sales | $19M | +76% |
| Net loss | $53M | vs. $107M profit |
| Net R&D expense | $48M | −34% |
| SG&A expense | $27M | −39% |
+47% from $9.00
| High | $19.00 |
| Low | $7.00 |
| Ratings | 2 Buy · 1 Hold · 1 Sell |
Approvals remove regulatory risk, but the stock's muted reaction signals demand uncertainty. The core sensitivities are vaccine uptake, coverage policy, Sanofi execution and timing of royalty recognition. Management gives no Sanofi sales forecast.
Sources: Novavax Aug. 28 approval update and Aug. 6 financial results; Reuters Aug. 27 FDA report; Google Finance. Prices are delayed U.S. quotes at 11:58 EDT on Aug. 28, 2026.
Reference points: $137.25 open, $147.77 high, $134.07 low, $137.86 latest.
Initial conversion equals roughly 3.1% of the June share base. The capped call is designed to offset dilution, but only up to its cap.
2032 maturityRule 144ASenior unsecured| Measure | Term | What it changes |
|---|---|---|
| Initial conversion | $210.58 | 47.5% premium to Thursday close |
| Capped-call ceiling | $392.6175 | Hedge protection to 175% premium |
| Expected net proceeds | $2.563bn | About 37% of June liquidity |
| Capped-call cost | $285m | About 11% of base net proceeds |
| Buyer option | Up to $400m | Could lift net proceeds near $2.96bn |
The financing replenishes flexibility after the settlement payment and ongoing research spending.
| Q2 revenue | $145m |
| Q2 EPS | −$1.97 |
| 2026 revenue plan | Up to +10% |
| Year-end cash guide | $4.7–$5.2bn |
| Analyst consensus | Hold |
| Average target | $106.63 |
Bull case: zero-coupon funding protects oncology momentum and the hedge limits dilution. Bear case: the stock remains above consensus value while cash burn and vaccine demand stay uncertain.
Intraday snapshot: August 27, 2026, 10:15:13 EDT
The stock recovered from its session low but remained 5.0% below Wednesday’s close.
The market erased about $2.97 billion while Moderna proposed $2.0 billion of base financing.
| Term | Current disclosure |
|---|---|
| Security | Senior unsecured convertible notes |
| Maturity | 2032 |
| Regular interest | None |
| Purchaser option | $300M for 13 days |
| Settlement | Cash, shares or both |
| Capped-call threshold | At least 150% premium at pricing |
| Metric | Amount | Read-through |
|---|---|---|
| Cash + investments | $6.9B | June 30 |
| Q2 operating cash outflow | $526M | Base notes = 3.8× |
| Q2 net loss | $782M | Base notes = 2.6× |
| July settlement payment | $950M | Post-quarter cash use |
| 2026 year-end cash guide | $4.7B–$5.2B | Before new deal update |
23 analysts · average target $104.53
Target dispersion is wide after the oncology-data rally. The financing terms now add a separate dilution and balance-sheet variable.
The financing converts part of the recent oncology revaluation into liquidity. No regular coupon limits cash interest, but conversion can expand the share count. The capped call only protects up to its final cap.
Pricing: conversion rate, premium and net proceeds.
Hedging: capped-call cost and counterparties’ trading.
Use of funds: oncology investment versus debt repayment.
Risk trigger: weaker clinical or regulatory progress after leverage rises.
Sources: Moderna August 27 financing announcement; Moderna July 31 quarterly results; Google Finance; MarketScreener. Calculations use the $142.20 share price and $56.54 billion market capitalization observed at 10:15:13 EDT on August 27, 2026. Values are rounded.
Stock move, valuation, trial evidence and cash runway
Financial figures reported July 31, 2026. A $950M settlement payment followed in July.
S&P Global consensus: Hold, 23 analysts; average target implies 37.2% downside from Tuesday's close.
| Measure | Reading | Investor meaning |
|---|---|---|
| INTerpath-001 enrollment | 1,137 patients | First positive Phase 3 individualized mRNA cancer-therapy readout |
| Treatment design | Up to 34 neoantigens; nine intismeran doses | Patient-specific manufacturing adds cost and turnaround risk |
| Phase 2b five-year result | 49% lower recurrence/death risk; 59% lower distant-metastasis/death risk | Supports mechanism, but Phase 3 effect size remains undisclosed |
| Moderna reaction | +176.97% on Aug. 19 | Largest direct platform repricing |
| Merck reaction | +12.6% on Aug. 19 | Extends the Keytruda franchise opportunity |
| BioNTech reaction | about +22% on Aug. 19 | Read-through for personalized mRNA oncology |
The August 25 rally added about $8.0 billion in value. Since the pre-readout close, the gain is about $38.3 billion. That premium now depends on regulatory timing, manufacturing economics and success beyond melanoma.
Hazard ratios, absolute event rates and overall-survival data are pending. Personalized production may constrain margins. Other tumors may not reproduce the melanoma result. Cash burn remains material.
−31.1% implied price gap. At current shares outstanding, that is about $17.3B of equity value.
| Firm | Rating | Target | Date |
|---|---|---|---|
| Barclays | Hold | $48 → $125 | Aug 24 |
| UBS | Hold | $50 → $150 | Aug 20 |
| Morgan Stanley | Hold | $39 → $89 | Aug 19 |
| Jefferies | Hold | $60 | Aug 19 |
| BofA | Hold | $40 → $170 | Aug 19 |
| Trial | Phase 3 INTerpath-001; 1,137 patients |
|---|---|
| Combination | Intismeran autogene + Keytruda |
| Result | Both primary endpoints met |
| Known | RFS and DMFS statistically significant |
| Not yet disclosed | Hazard ratios, absolute curves, filing timetable |
| Next trigger | Medical-meeting presentation or regulatory guidance |
| Metric | 2026E | 2027E |
|---|---|---|
| Revenue | $2.11B | $2.46B |
| Growth | +8.35% | +16.66% |
| EPS | −$8.62 | −$4.58 |
Year-end 2026 cash forecast: $4.7B–$5.2B
| Scenario | What changes | Likely read-through |
|---|---|---|
| Bull | Large effect, clean safety, quick filing | Pipeline value broadens across tumors |
| Base | Clinically useful result, normal review | Wide target range persists |
| Bear | Modest effect or manufacturing friction | Premium over consensus compresses |
Market data as of August 21, 2026, 16:00 EDT (22:00 CEST). U.S. market closed.
| Firm | Rating | Target | Gap |
|---|---|---|---|
| BofA | Hold | $170 | +17.1% |
| UBS | Hold | $150 | +3.4% |
| Goldman | Hold | $120 | -17.3% |
| Morgan Stanley | Hold | $89 | -38.7% |
| Consensus | Neutral | $78.78 | -45.7% |
| Phase 3 patients | 1,137 |
| Prior Phase 2b recurrence/death reduction | 49% |
| Q2 revenue | $145M |
| Q2 GAAP net loss | $782M |
| June cash and investments | $6.9B |
| 2026 year-end cash outlook | $4.7B-$5.2B |
Sources: Moderna and Merck Phase 3 release, Moderna Q2 2026 SEC filing, Nasdaq/Yahoo Finance closing data, Investing.com analyst targets, S3 Partners estimate reported by Business Times. Percentages are calculated from cited closes and targets. This dashboard is informational, not investment advice.
Moderna · NASDAQ:MRNA
Day range $132.42–$159.47 · Volume 86.74M vs. 15.08M average
$62.96 before the readout to $145.13 Friday.
$82.17 per share × 399.24M shares.
About 8.4× June cash and investments.
Before the $950M litigation payment made in July.
INTerpath-001 enrolled 1,137 melanoma patients and met recurrence-free and distant-metastasis-free survival endpoints. No new safety signal emerged. The full Phase 3 hazard ratios, confidence intervals, subgroup results and overall-survival data remain undisclosed. Investors have added $32.81 billion of equity value without the effect size.
Risk: the price can reverse if detailed efficacy, safety or regulatory timing falls short of the expectations embedded in the rally.
Sources: Google Finance · Phase 3 release · SEC Q2 filing
| Checkpoint | Current state | Why it matters |
|---|---|---|
| Full Phase 3 data | Topline only | Tests the size and durability of benefit |
| Regulatory path | Discussions planned | Sets filing timing and evidence burden |
| Other tumors | Eight-trial program | Needed to support platform valuation |
| Manufacturing | Individualized | Determines speed, scale and margins |
The scientific milestone is real. The commercial case is still preliminary.
Market data: August 19, 2026 close, 16:00 EDT
Prepared after the U.S. session
Highest close in about three years
Phase 3 melanoma readout
One session, Financial Times estimate
Close × 399.24M shares
Investor read: the market priced a platform, not just a melanoma product. The $44 billion value gain equals about 14.7× Barclays’ $3 billion estimate for 2035 melanoma sales.
INTerpath-001 enrolled 1,137 patients with resected stage IIB-IV melanoma. No new safety signal was reported.
| Firm | View | Target |
|---|---|---|
| Piper Sandler | Overweight | $77 |
| Goldman Sachs | Neutral | $67 |
| Citigroup | Neutral | $60 |
| RBC Capital | Sector Perform | $45 |
| Wolfe Research | Underperform | $25 |
The $174.38 close is 126% above the old high target and 243% above the $50.84 consensus. These targets have not absorbed the trial result.
Bars share a $44 billion scale. The sales figure is an analyst estimate for melanoma in 2035, not company guidance.
| Next U.S. session | August 20, 09:30 EDT |
| Analyst model resets | Watch targets and probability assumptions |
| Medical presentation | Date not yet disclosed |
| Regulatory path | Companies are already in discussions |
| Possible availability | 2027, subject to approval |
Merck's value gain was nearly 18 times one published valuation for the melanoma program.
A melanoma approval is only the first layer. The premium also reflects Keytruda lifecycle extension and shots in other tumors.
$8.37 billion of Q2 sales came from the Keytruda franchise—50.4% of Merck's $16.61 billion total.
The average target sat 11.2% below the intraday price. Even the high target offered just 1.2% upside.
S&P 500 • INDEXSP:SPX
Intraday, not a closing value
+45.89 points
-53.30 points
Wednesday gain ÷ Tuesday loss
Technology carried a 36.8% S&P 500 weight on July 31. Healthcare held 9.1%.
| Firm | Target | Upside | Stance |
|---|---|---|---|
| Citigroup | 8,100 | 4.7% | Constructive |
| JPMorgan | 8,000 | 3.4% | Constructive |
| Goldman Sachs | 8,000 | 3.4% | Constructive |
| UBS | 7,900 | 2.1% | Constructive |
Upside is measured against 7,737.65. “Constructive” summarizes targets above the market, not a formal index rating.
| Metric | Value |
|---|---|
| Q2 revenue | $145M |
| Q2 GAAP net loss | $(782)M |
| June 30 cash & investments | $6.9B |
| July settlement payment | $(950)M |
| 2026 year-end cash guide | $4.7–5.2B |
